Drug intelligence / Profile preview

fosrolapitant

Development stage: Phase 4
Lead developer: Fujian Shengdi Pharmaceuticals
Modality: Small Molecules
Administration: Injection, Parenteral

Overview

Fosrolapitant (HRS5580) is a prodrug of rolapitant being developed by Fujian Shengdi Pharmaceutical. It functions as a neurokinin 1 receptor (NK-1R) antagonist that prevents postoperative nausea and vomiting. The drug features a long half-life and high central nervous system permeability, making it particularly suitable for patients with prolonged postoperative vomiting. Once administered, HRS5580 is rapidly converted into rolapitant through non-CYP450 enzyme systems like thiol methyltransferase.

Other names: Rolapitant PRODRUG

Targets

TACR1 (Neurokinin‑1 Receptor)

Beyond the preview

Go deeper on fosrolapitant.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on fosrolapitant.

Explore the full profile